EyeGate is developing and commercializing products for treating diseases and disorders of the eye. The Companyâs products are based on two proprietary platform technologies: EyeGateâs first platform is based on a cross-linked thiolated carboxymethyl hyaluronic acid (âCMHA-Sâ), a modified form of the natural polymer hyaluronic acid (âHAâ), which is a gel that possesses unique physical and chemical properties including hydration and healing when applied to the ocular surface. The ability of CMHA-S to protect and adhere longer to the ocular surface, and resist degradation makes it well-suited for treating various ocular surface injuries. EGP-437, EyeGateâs second product in clinical trials, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues through EyeGateâs proprietary innovative drug delivery system, the EyeGate II Delivery System. EGP-437 is currently in trials for the treatment of uveitis and pain and inflammation following cataract surgery. EyeGate has granted a subsidiary of Valeant Pharmaceuticals an exclusive worldwide license to the product in these indications. Source
No articles found.
Cue Biopharma is an innovative clinical stage immunotherapy company developing a n...
Cue Biopharma is an innovative clinical stage i...
Generex Biotechnology is an integrated healthcare holding company with end-to-end ...
Generex Biotechnology is an integrated healthca...
ICU Medical, Inc. (Nasdaq:ICUI) develops, manufactures and sells innovative medica...
ICU Medical, Inc. (Nasdaq:ICUI) develops, manuf...
CytoDyn is a publicly traded late stage biotechnology company developing innovativ...
CytoDyn is a publicly traded late stage biotech...
TherapeuticsMD, Inc. is an innovative pharmaceutical company exclusively committed...
TherapeuticsMD, Inc. is an innovative pharmaceu...
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company seeking to advance targe...
AVEO Pharmaceuticals, Inc. is a biopharmaceutic...
Join the National Investor Network and get the latest information with your interests in mind.